6-(3-piperidin-1-ylpropoxy)-3,4-dihydro-2H-isoquinolin-1-one | 464898-88-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 6-(3-piperidin-1-ylpropoxy)-3,4-dihydro-2H-isoquinolin-1-one
• CAS: 464898-88-2
• 化学式: C₁₇H₂₄N₂O₂
• 分子量: 288.39
• InChiKey: LUNFWKLMVOOCLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(3-piperidin-1-ylpropoxy)-3,4-dihydro-2H-isoquinolin-1-one 、 (3R)-3-deoxo-11-deoxy-3-methoxy-11-oxo-4-epi-mutilin 14-chloroformate 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 (3R,3aS,4R,5R,7S,9R,9aR,12R)-3-methoxy-4,7,9,12-tetramethyl-8-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 1-oxo-6-(3-(piperidin-1-yl)propoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationship studies of conformationally restricted mutilin 14-carbamates

  摘要：

  We report herein the design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates based on the structure of SB-222734. The antibacterial activities of these newly synthesized compounds were also evaluated and compared with linezolid and retapamulin. Results showed that most of the target compounds exhibit good potency in inhibiting the growth of Gram-positive bacteria including Methicillin-susceptible Staphylococcus aureus MSSA (MIC: 0.0625-2 mu g/mL), Methicillin-resistant S. aureus MRSA (MIC: 0.0625-2 mu g/mL), Methicillin-susceptible Staphylococcus epidermidis MSSE (MIC: 0.0625-2 mu g/mL), Methicillin-resistant S. epidermidis MRSE (MIC: 0.0625-2 mu g/mL), and Streptococcus pneumonia (MIC: 0.0625-4 mu g/mL). In particular, three remarkable compounds of this series (12l, 12m, and 21l) exhibited comparable in vitro antibacterial profiles to that of retapamulin. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.063
• 作为产物：
  描述：

  3-甲氧基苯乙基氨基甲酸乙酯 在 三溴化硼 、 potassium carbonate 、 sodium iodide 作用下， 以 四氢呋喃 、 二氯甲烷 、 丙酮 为溶剂， 反应 18.0h， 生成 6-(3-piperidin-1-ylpropoxy)-3,4-dihydro-2H-isoquinolin-1-one
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationship studies of conformationally restricted mutilin 14-carbamates

  摘要：

  We report herein the design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates based on the structure of SB-222734. The antibacterial activities of these newly synthesized compounds were also evaluated and compared with linezolid and retapamulin. Results showed that most of the target compounds exhibit good potency in inhibiting the growth of Gram-positive bacteria including Methicillin-susceptible Staphylococcus aureus MSSA (MIC: 0.0625-2 mu g/mL), Methicillin-resistant S. aureus MRSA (MIC: 0.0625-2 mu g/mL), Methicillin-susceptible Staphylococcus epidermidis MSSE (MIC: 0.0625-2 mu g/mL), Methicillin-resistant S. epidermidis MRSE (MIC: 0.0625-2 mu g/mL), and Streptococcus pneumonia (MIC: 0.0625-4 mu g/mL). In particular, three remarkable compounds of this series (12l, 12m, and 21l) exhibited comparable in vitro antibacterial profiles to that of retapamulin. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.063

文献信息

• Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
  申请人：——

  公开号：US20040110748A1

  公开（公告）日：2004-06-10

  The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases. 1

  本发明公开了新型取代芳基烷基胺化合物的化学式（I）或其医药上可接受的盐，它们具有选择性的组胺H3受体拮抗活性，以及制备这些化合物的方法。在另一种实施方式中，本发明公开了包含这些环状胺的药物组合物，以及使用它们治疗肥胖症和其他组胺H3受体相关疾病的方法。
• US7314937B2
  申请人：——

  公开号：US7314937B2

  公开（公告）日：2008-01-01
• Design, synthesis, and structure–activity relationship studies of conformationally restricted mutilin 14-carbamates
  作者：Liqiang Fu、Xin Liu、Chenyu Ling、Jianjun Cheng、Xingsheng Guo、Huili He、Shi Ding、Yushe Yang

  DOI：10.1016/j.bmcl.2011.12.063

  日期：2012.1

  We report herein the design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates based on the structure of SB-222734. The antibacterial activities of these newly synthesized compounds were also evaluated and compared with linezolid and retapamulin. Results showed that most of the target compounds exhibit good potency in inhibiting the growth of Gram-positive bacteria including Methicillin-susceptible Staphylococcus aureus MSSA (MIC: 0.0625-2 mu g/mL), Methicillin-resistant S. aureus MRSA (MIC: 0.0625-2 mu g/mL), Methicillin-susceptible Staphylococcus epidermidis MSSE (MIC: 0.0625-2 mu g/mL), Methicillin-resistant S. epidermidis MRSE (MIC: 0.0625-2 mu g/mL), and Streptococcus pneumonia (MIC: 0.0625-4 mu g/mL). In particular, three remarkable compounds of this series (12l, 12m, and 21l) exhibited comparable in vitro antibacterial profiles to that of retapamulin. (C) 2011 Elsevier Ltd. All rights reserved.